<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25391139</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>12</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1469-493X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2014</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Nov</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Cochrane database of systematic reviews</Title>
          <ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).</ArticleTitle>
        <Pagination>
          <StartPage>CD003458</StartPage>
          <MedlinePgn>CD003458</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">CD003458</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD003458.pub5</ELocationID>
        <Abstract>
          <AbstractText>Background McArdle disease (Glycogen Storage Disease type V) is caused by an absence of muscle phosphorylase leading to exercise intolerance,myoglobinuria rhabdomyolysis and acute renal failure. This is an update of a review first published in 2004.Objectives To review systematically the evidence from randomised controlled trials (RCTs) of pharmacological or nutritional treatments for improving exercise performance and quality of life in McArdle disease.Search methods We searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE and EMBASE on 11 August 2014.Selection criteria We included RCTs (including cross-over studies) and quasi-RCTs. We included unblinded open trials and individual patient studies in the discussion. Interventions included any pharmacological agent or nutritional supplement. Primary outcome measures included any objective assessment of exercise endurance (for example aerobic capacity (VO2) max, walking speed, muscle force or power and fatigability). Secondary outcome measures included metabolic changes (such as reduced plasma creatine kinase and a reduction in the frequency of myoglobinuria), subjective measures (including quality of life scores and indices of disability) and serious adverse events.Data collection and analysis Three review authors checked the titles and abstracts identified by the search and reviewed the manuscripts. Two review authors independently assessed the risk of bias of relevant studies, with comments from a third author. Two authors extracted data onto a specially designed form.Main results We identified 31 studies, and 13 fulfilled the criteria for inclusion. We described trials that were not eligible for the review in the Discussion. The included studies involved a total of 85 participants, but the number in each individual trial was small; the largest treatment trial included 19 participants and the smallest study included only one participant. There was no benefit with: D-ribose,glucagon, verapamil, vitamin B6, branched chain amino acids, dantrolene sodium, and high-dose creatine. Minimal subjective benefit was found with low dose creatine and ramipril only for patients with a polymorphism known as the D/Dangiotens in converting enzyme(ACE) phenotype. A carbohydrate-rich diet resulted in better exercise performance compared with a protein-rich diet. Two studies of oral sucrose given at different times and in different amounts before exercise showed an improvement in exercise performance. Four studies reported adverse effects. Oral ribose caused diarrhoea and symptoms suggestive of hypoglycaemia including light-headedness and hunger. In one study, branched chain amino acids caused a deterioration of functional outcomes. Dantrolene was reported to cause a number of adverse effects including tiredness, somnolence, dizziness and muscle weakness. Low dose creatine (60 mg/kg/day) did not cause side-effects but high-dose creatine (150 mg/kg/day) worsened the symptoms of myalgia.Authors' conclusions Although there was low quality evidence of improvement in some parameters with creatine, oral sucrose, ramipril and a carbohydrate rich diet, none was sufficiently strong to indicate significant clinical benefit.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Quinlivan</LastName>
            <ForeName>Rosaline</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martinuzzi</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schoser</LastName>
            <ForeName>Benedikt</ForeName>
            <Initials>B</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cochrane Database Syst Rev</MedlineTA>
        <NlmUniqueID>100909747</NlmUniqueID>
        <ISSNLinking>1361-6137</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004040">Dietary Carbohydrates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004044">Dietary Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>57-50-1</RegistryNumber>
          <NameOfSubstance UI="D013395">Sucrose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>L35JN3I7SJ</RegistryNumber>
          <NameOfSubstance UI="D017257">Ramipril</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>MU72812GK0</RegistryNumber>
          <NameOfSubstance UI="D003401">Creatine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="UpdateOf">
          <RefSource>Cochrane Database Syst Rev. 2010;(12):CD003458</RefSource>
          <PMID Version="1">21154353</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003401" MajorTopicYN="N">Creatine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004040" MajorTopicYN="N">Dietary Carbohydrates</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004044" MajorTopicYN="N">Dietary Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006012" MajorTopicYN="N">Glycogen Storage Disease Type V</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010807" MajorTopicYN="N">Physical Endurance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017257" MajorTopicYN="N">Ramipril</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013395" MajorTopicYN="N">Sucrose</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>RQ was involved in the conduct of a randomised cross‐over placebo‐controlled trial of vitamin B<sub>6</sub>, which did not demonstrate any overall benefit. RQ received an honorarium from Genzyme in July 2010 for lecturing on metabolic muscle disease. She has a grant from the muscular dystrophy campaign and European Union for McArdle disease research. AM was involved in the conduct of a RCT of ramipril which did not demonstrate any significant benefit. In relation to this trial his institution received a project grant from Telethon, Italy. His institution also received an European Union grant for the EUROMAC project, establishing a European registry for muscle glycogenoses. BS was involved in an unblinded observational study of high fat diet which showed no benefit. BS has received payment for membership of the Genzyme Pompe disease advisory board and for advice on Pompe disease to Biomarin Ltd. He has received payment for lectures from Genzyme, Biomarin and CSL Behring.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>12</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25391139</ArticleId>
        <ArticleId IdType="pmc">PMC7173724</ArticleId>
        <ArticleId IdType="doi">10.1002/14651858.CD003458.pub5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References to studies included in this review</Title>
        <ReferenceList>
          <Title>Andersen 2008a {published data only}</Title>
          <Reference>
            <Citation>Andersen ST, 
Vissing J. 
Carbohydrate‐ and protein‐rich diets in McArdle disease: effects on exercise capacity. 
Journal of Neurology, Neurosurgery &amp; Psychiatry 2008;79(12):1359‐63. 
[PUBMED: 19010947]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">19010947</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Andersen 2008b {published data only}</Title>
          <Reference>
            <Citation>Andersen ST, 
Haller RG, 
Vissing J. 
Effect of oral sucrose before exercise on work capacity in McArdle disease. 
Archives of Neurology 2008;65(6):786‐9. 
[PUBMED: 18541798]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">18541798</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Beynon 1998 {unpublished data only}</Title>
          <Reference>
            <Citation>Beynon RJ, 
Quinlivan RCM, 
Hopkins P, 
White L, 
Bartram C, 
Phoenix J. 
McArdle's disease: molecular genetics, clinical heterogeneity and a therapeutic trial. 
Muscle &amp; Nerve 1998;30 Suppl:30.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Day 1985 {published data only}</Title>
          <Reference>
            <Citation>Day TJ, 
Mastaglia FL. 
Depot‐glucagon in the treatment of McArdle's disease. 
Australian and New Zealand Journal of Medicine 1985;15(6):748‐50. 
[PUBMED: 3869441]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">3869441</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kushner 1990 {published data only}</Title>
          <Reference>
            <Citation>Kushner RF, 
Berman SA. 
Are high‐protein diets effective in McArdle's Disease?. 
Archives of Neurology 1990;47(4):383‐4. 
[PUBMED: 2322130]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">2322130</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Lane 1986 {published data only}</Title>
          <Reference>
            <Citation>Lane RJ, 
Turnbull DM, 
Welch JL, 
Walton J. 
A double‐blind placebo‐controlled crossover study of verapamil in exertional muscle pain. 
Muscle &amp; Nerve 1986;9(7):635‐41. 
[PUBMED: 3531845]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">3531845</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>MacLean 1998 {published data only}</Title>
          <Reference>
            <Citation>MacLean D, 
Vissing J, 
Vissing SF, 
Haller RG. 
Oral branched‐chain amino acids do not improve exercise capacity in McArdle disease. 
Neurology 1998;51(5):1456‐9. 
[PUBMED: 9818881]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">9818881</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Martinuzzi 2008 {published data only}</Title>
          <Reference>
            <Citation>Martinuzzi A, 
Liava A, 
Trevisi E, 
Antoniazzi L, 
Frare M. 
Chronic therapy for McArdle disease: the randomized controlled trial with ACE inhibitor. 
Acta Myologica 2007;26(1):64‐6. 
[PUBMED: 17915574]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC2949319</ArticleId>
              <ArticleId IdType="pubmed">17915574</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Martinuzzi A, 
Liava A, 
Trevisi E, 
Frare M, 
Tonon C, 
Malucelli E, 
et al. 
Randomised, placebo‐controlled, double‐blind pilot trial of ramipril in McArdle's disease. 
Muscle &amp; Nerve 2008;37(3):350‐7. 
[PUBMED: 18098237]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">18098237</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Poels 1990 {published data only}</Title>
          <Reference>
            <Citation>Poels PJ, 
Braakhekke JP, 
Joosten EM, 
Stegeman DF. 
Dantrolene sodium does influence the second‐wind phenomenon in McArdle's disease. Electrophysioloical evidence during exercise in a double‐blind placebo‐controlled, cross‐over study in 5 patients. 
Journal of the Neurological Sciences 1990;100(1‐2):108‐12. 
[PUBMED: 2089128]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">2089128</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Steele 1996 {published data only}</Title>
          <Reference>
            <Citation>Steele IC, 
Patterson VH, 
Nicholls DP. 
A double blind, placebo controlled, crossover trial of D‐ribose in McArdle's disease. 
Journal of the Neurological Sciences 1996;136(1‐2):174‐7. 
[PUBMED: 8815168]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">8815168</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Vissing 2003 {published data only}</Title>
          <Reference>
            <Citation>Vissing J, 
Haller RG. 
The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. 
New England Journal of Medicine 2003;349(26):2503‐9. 
[PUBMED: 14695410]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">14695410</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Vorgerd 2000 {published data only}</Title>
          <Reference>
            <Citation>Vorgerd M, 
Grehl T, 
Jager M, 
Muller K, 
Freitag G, 
Patzold T, 
et al. 
Creatine therapy in myophosphorylase deficiency (McArdle disease). A placebo‐controlled crossover trial. 
Archives of Neurology 2000;57(7):956‐63. 
[PUBMED: 10891977]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">10891977</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Vorgerd 2002 {published data only}</Title>
          <Reference>
            <Citation>Vorgerd M, 
Zange J, 
Kley R, 
Grehl T, 
Husing A, 
Jager M, 
et al. 
Effect of high‐dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double‐blind, placebo‐controlled crossover study. 
Archives of Neurology 2002;59(1):97‐101. 
[PUBMED: 11790236]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">11790236</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
      </ReferenceList>
      <ReferenceList>
        <Title>References to studies excluded from this review</Title>
        <ReferenceList>
          <Title>Andersen 2009 {published data only}</Title>
          <Reference>
            <Citation>Andersen ST, 
Jeppesen TD, 
TaivassaloT, 
Sveen ML, 
Heinicke K, 
Haller RG, 
et al. 
Effect of changes in fat availability on exercise capacity in McArdle disease. 
Archives of Neurology 2009;66(6):762‐6.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">19506137</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Busch 2005 {published data only}</Title>
          <Reference>
            <Citation>Busch V, 
Gempel K, 
Hack A, 
Muller K, 
Vorgerd M, 
Lochmuller H, 
et al. 
Treatment of glycogenosis type V with ketogenic diet. 
Annals of Neurology 2005;58(2):341.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">16049943</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Haller 2002 {published data only}</Title>
          <Reference>
            <Citation>Haller RG, 
Vissing J. 
Spontaneous "second wind" and glucose‐induced "second wind" in McArdle disease. 
Archives of Neurology 2002;59(9):1395‐402.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">12223025</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Jensen 1990 {published data only}</Title>
          <Reference>
            <Citation>Jensen KE, 
Jacobson J, 
Thomsen C, 
Henriksen O. 
Improved energy kinetics following high protein diet in McArdle's syndrome. A 31P magnetic resonance spectroscopy study. 
Acta Neurologica Scandinavica 1990;81(6):499‐503.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">2220306</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kono 1984 {published data only}</Title>
          <Reference>
            <Citation>Kono N, 
Mineo I, 
Sumi S, 
Shimizu T, 
Kang J, 
Nonaka K, 
et al. 
Metabolic basis of improved exercise tolerance: Muscle phosphorylase deficiency after glucagon administration. 
Neurology 1984;34(11):1471‐76.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">6593602</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Lewis 1985 {published data only}</Title>
          <Reference>
            <Citation>Lewis SF, 
Haller RG, 
Cook JD, 
Nunnally RL. 
Muscle fatigue in McArdle's disease studied by 31P‐NMR: effect of glucose infusion. 
Journal of Applied Physiology 1985;59(6):1991‐4.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">3865926</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Mineo 1984 {published data only}</Title>
          <Reference>
            <Citation>Mineo I, 
Kono N, 
Shimizu T, 
Sumi S, 
Nonaka K, 
Tarui S. 
A comparative study on glucagon effect between McArdle disease and Tarui disease. 
Muscle &amp; Nerve 1984;7(7):552‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">6242422</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>O'Reilly 2003 {published data only}</Title>
          <Reference>
            <Citation>O'Reilly DS, 
Carter R, 
Bell E, 
Hinnie J, 
Galloway PJ. 
Exercise to exhaustion in the second‐wind phase of exercise in case of McArdle's disease with and without creatine supplementation. 
Scottish Medical Journal 2003;48(2):46‐8.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">12774595</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Phoenix 1998 {published data only}</Title>
          <Reference>
            <Citation>Phoenix J, 
Hopkins P, 
Bartram C, 
Beynon R, 
Quinlivan RC, 
Edwards RHT. 
Effect of vitamin B6 supplementation in McArdle's disease: a strategic case study. 
Neuromuscular Disorders 1998;8(3‐4):210‐2.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">9631404</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Schoser 2008 {unpublished data only}</Title>
          <Reference>
            <Citation>Schoser B. 
Individual patient data (supplied 2008). 
Data on file.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Schroers 2006 {published data only}</Title>
          <Reference>
            <Citation>Schroers A, 
Kley R, 
Stachon A, 
Horvath R, 
Lochmuller H, 
Gange J, 
et al. 
Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficiency. 
Neurology 2006;66(2):285‐6.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">16434679</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Slonim 1985 {published data only}</Title>
          <Reference>
            <Citation>Slonim A E, 
Goans PJ. 
Myopathy in McArdle's syndrome: improvement with a high protein diet. 
New England Journal of Medicine 1985;312(6):355‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">3855499</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Viskoper 1975 {published data only}</Title>
          <Reference>
            <Citation>Viskoper R, 
Wolf E, 
Chaco J, 
Katz R, 
Chowers I. 
McArdle's syndrome: the reaction to a fat rich diet. 
American Journal of Medical Sciences 1975;269(2):217‐21.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">1056701</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Vorgerd 2007 {published data only}</Title>
          <Reference>
            <Citation>Vorgerd M, 
Zange J. 
Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P‐MRS on working leg muscle. 
Acta Myologica 2007;26(2):61‐3.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC2949316</ArticleId>
              <ArticleId IdType="pubmed">17915573</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Wagner 1991 {published data only}</Title>
          <Reference>
            <Citation>Wagner D R, 
Zollner N. 
McArdle's disease: successful symptomatic therapy by high dose oral administration of ribose. 
Klinische Wochenschrift 1991;69(2):92.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">1902882</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
      </ReferenceList>
      <ReferenceList>
        <Title>Additional references</Title>
        <ReferenceList>
          <Title>Andreu 2007</Title>
          <Reference>
            <Citation>Andreu A, 
Nogales‐Gadea G, 
Cassandrini D, 
Arenas J, 
Bruno C. 
McArdle disease: molecular genetic update. 
Acta Myologica 2007;26(1):53‐7.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC2949323</ArticleId>
              <ArticleId IdType="pubmed">17915571</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Barton‐Davis 1999</Title>
          <Reference>
            <Citation>Barton‐Davis ER, 
Cordier L, 
Shoturma DI, 
Leland SE, 
Sweeney HL. 
Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. 
Journal of Clinical Investigation 1999;104(4):375‐81.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC481050</ArticleId>
              <ArticleId IdType="pubmed">10449429</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Bartram 1993</Title>
          <Reference>
            <Citation>Bartram C, 
Edwards RHT, 
Clague J, 
Beynon R. 
McArdle's disease: a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases. 
Human Molecular Genetics 1993;2(8):1291‐3.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">8401511</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Bertorini 1982</Title>
          <Reference>
            <Citation>Bertorini T, 
Palmieri G, 
Bhattacharya S. 
Beneficial effects of dantrolene sodium in exercise‐induced muscle pains: calcium mediated?. 
Lancet 1982;1(8272):616‐7.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">6121197</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Beynon 1995</Title>
          <Reference>
            <Citation>Beynon RJ, 
Bartram C, 
Hopkins P, 
Toesco V, 
Gibson H, 
Phoenix J, 
et al. 
McArdle's disease: molecular genetics and metabolic consequences of the phenotype. 
Muscle &amp; Nerve 1995;3:S18‐22.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">7603521</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Borg 1982</Title>
          <Reference>
            <Citation>Borg GA. 
Psychophysical bases of perceived exertion. 
Medicine and Science in Sports and Exercise 1982;14(5):377‐81.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">7154893</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>De Stefano 1996</Title>
          <Reference>
            <Citation>Stefano N, 
Argov Z, 
Matthews PM, 
Karpati G, 
Arnold DL. 
Impairment of muscle mitochondrial oxidative metabolism in McArdle's disease. 
Muscle &amp; Nerve 1996;19(6):764‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">8609928</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Gomez‐Gallego 2007</Title>
          <Reference>
            <Citation>Gómez‐Gallego F, 
Santiago C, 
Morán M, 
Perez M, 
Maté‐Munoz JL, 
Fernández Del Valle M, 
et al. 
The I allele of the ACE gene is associated with improvement in exercise capacity in women with McArdle disease. 
British Journal of Sports Medicine 2008;42:134‐40.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">17616548</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Haller 1983</Title>
          <Reference>
            <Citation>Haller R G, 
Dempsey W B, 
Feit H, 
Cook J D, 
Knochel JP. 
Low levels of muscle pyridoxine in McArdle's syndrome. 
American Journal of Medicine 1983;74(2):217‐20.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">6572033</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Higgins 2008</Title>
          <Reference>
            <Citation>Higgins JPT, 
Green S (editors). 
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. 
The Cochrane Collaboration, 2009. Available from www.cochrane‐handbook.org.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Higgins 2011</Title>
          <Reference>
            <Citation>Higgins JPT, 
Green S (editors). 
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. 
The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kubisch 1998</Title>
          <Reference>
            <Citation>Kubisch C, 
Wicklein EM, 
Jentsch TJ. 
Molecular diagnosis of McArdle's disease: revised genomic structure of the phosphorylase gene and identification of a novel mutation. 
Human Mutation 1998;12:27‐32.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">9633816</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Libonati 1998</Title>
          <Reference>
            <Citation>Libonati JR, 
Cox M, 
Incanno N, 
Melville SK, 
Musante FC, 
Glassberg HL, 
et al. 
Brief periods of occlusion and re‐perfusion increase skeletal muscle force output in humans. 
Cardiologia 1998;43(12):1355‐60.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">9988944</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Lucia 2007</Title>
          <Reference>
            <Citation>Lucia A, 
Gomez‐Gallego F, 
Santiago C, 
Perez M, 
Mate‐Munoz JL, 
Chamorro‐Vina C, 
et al. 
The 577X allele of the ACTN3 gene is associated with improved exercise capacity in women with McArdle's disease. 
Neuromuscular Disorders 2007;17(8):603‐10.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">17560787</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Martinuzzi 2003</Title>
          <Reference>
            <Citation>Martinuzzi A, 
Sartori E, 
Fanin M, 
Nascimbeni A, 
Valente L, 
Angelini C, 
et al. 
Phenotype modulators in myophosphorylase deficiency. 
Annals of Neurology 2003;53(4):497‐502.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">12666117</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>McArdle 1951</Title>
          <Reference>
            <Citation>McArdle B. 
Myopathy due to a defect in muscle glycogen breakdown. 
Clinical Science 1951;10:13‐33.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">24540673</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Mommaerts 1959</Title>
          <Reference>
            <Citation>Mommaerts WFH, 
Illingworth B, 
Pearson CM, 
Guilorg RJ, 
Seraydarian K. 
A functional disorder of muscle associated with the absence of phosphorylase. 
Proceedings of the National Academy of Science USA 1959;3:18‐22.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC222638</ArticleId>
              <ArticleId IdType="pubmed">16590445</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Orngreen 2009</Title>
          <Reference>
            <Citation>Orngreen MC, 
Jeppesen TD, 
Andersen ST, 
Taivassalo T, 
Hauerslev S, 
Priesler N, 
et al. 
Fat metabolism during exercise in patients with McArdle disease. 
Neurology 2009;72(8):718‐24.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">19237700</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Pearson 1961</Title>
          <Reference>
            <Citation>Pearson CM, 
Rimor DG, 
Mommaerts WFHM. 
A metabolic myopathy due to absence of muscle phosphorylase. 
American Journal of Medicine 1961;30:502‐17.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">13733779</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Quinlivan 2011</Title>
          <Reference>
            <Citation>Quinlivan R, 
Vissing J, 
Hilton‐Jones D, 
Buckley J. 
Physical training for McArdle disease. 
Cochrane Database of Systematic Reviews 2011, Issue 12. 
[DOI: 10.1002/14651858.CD007931.pub2]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1002/14651858.CD007931.pub2</ArticleId>
              <ArticleId IdType="pubmed">22161416</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>RevMan 2014 [Computer program]</Title>
          <Reference>
            <Citation>The Nordic Cochrane Centre, The Cochrane Collaboration. 
Review Manager (RevMan). 
Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Rubio 2007</Title>
          <Reference>
            <Citation>Rubio JC, 
Gomez‐Gallego F, 
Santiago C, 
Garcia‐Consuegra I, 
Perez M, 
Barriopedro MI, 
et al. 
Genotype modulators of clinical severity in McArdle disease. 
Neuroscience Letters 2007;422(3):217‐22.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">17630210</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Ruff 1998</Title>
          <Reference>
            <Citation>Ruff RL. 
Why do patients with McArdle's disease have decreased exercise capacity?. 
Neurology 1998;50(1):6‐7.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">9443449</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Schmidt 1959</Title>
          <Reference>
            <Citation>Schmidt R, 
Mahler R. 
Chronic progressive myopathy with myoglobinuria: demonstration of a glycogenolytic defect in muscle. 
Journal of Clinical Investigation 1959;108:2044‐58.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC441792</ArticleId>
              <ArticleId IdType="pubmed">14442994</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Tarnopolsky 1997</Title>
          <Reference>
            <Citation>Tarnopolsky MA, 
Roy BD, 
MacDonald JR. 
A randomised controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. 
Muscle &amp; Nerve 1997;20:1502‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">9390662</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Vandenberghe 1997</Title>
          <Reference>
            <Citation>Vandenberghe K, 
Goris M, 
Hecke P, 
Leemputte M, 
Vangerven L, 
Hespel P. 
Long term creatine intake is beneficial to muscle performance during resistance training. 
Journal of Applied Physiology 1997;83(6):2055‐63.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">9390981</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Vissing 1998</Title>
          <Reference>
            <Citation>Vissing J, 
Vissing SF, 
Maclean D, 
Saltin B, 
Quistorff B, 
Haller RJ. 
Sympathetic activation in exercise is not dependent on muscle acidosis. Direct evidence from studies in metabolic myopathies. 
Journal of Clinical Investigation 1998;108(8):1654‐60.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC508746</ArticleId>
              <ArticleId IdType="pubmed">9541495</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
      </ReferenceList>
      <ReferenceList>
        <Title>References to other published versions of this review</Title>
        <ReferenceList>
          <Title>Quinlivan 2002</Title>
          <Reference>
            <Citation>Quinlivan RCM, 
Beynon R. 
Pharmacological and nutritional treatment for McArdle's disease (Glycogen storage disease type V). 
Cochrane Database of Systematic Reviews 2002, Issue 1. 
[DOI: 10.1002/14651858.CD003458]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1002/14651858.CD003458</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Quinlivan 2004</Title>
          <Reference>
            <Citation>Quinlivan R, 
Beynon RJ. 
Pharmacological and nutritional treatment for McArdle's disease (Glycogen Storage Disease type V). 
Cochrane Database of Systematic Reviews 2004, Issue 3. 
[DOI: 10.1002/14651858.CD003458.pub2]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1002/14651858.CD003458.pub2</ArticleId>
              <ArticleId IdType="pubmed">15266486</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Quinlivan 2008</Title>
          <Reference>
            <Citation>Quinlivan R, 
Beynon RJ, 
Martinuzzi A. 
Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V). 
Cochrane Database of Systematic Reviews 2008, Issue 2. 
[DOI: 10.1002/14651858.CD003458.pub3]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1002/14651858.CD003458.pub3</ArticleId>
              <ArticleId IdType="pubmed">18425888</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Quinlivan 2010</Title>
          <Reference>
            <Citation>Quinlivan R, 
Martinuzzi A, 
Schoser B. 
Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V). 
Cochrane Database of Systematic Reviews 2010, Issue 12. 
[DOI: 10.1002/14651858.CD003458.pub4]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1002/14651858.CD003458.pub4</ArticleId>
              <ArticleId IdType="pubmed">21154353</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
